Earnings Feed
Start Free
Entrada Therapeutics, Inc.·4

Mar 3, 6:21 PM ET

Doshi Dipal 4

4 · Entrada Therapeutics, Inc. · Filed Mar 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Entrada (TRDA) CEO Dipal Doshi Receives RSUs; Shares Sold for Taxes

What Happened

  • Dipal Doshi, CEO and Director of Entrada Therapeutics (TRDA), received two awards of restricted stock units (RSUs) on 2026-03-01 totaling 347,400 RSUs (139,400 and 208,000). Both grants are reported at $0.00 (award/derivative acquisition).
  • To satisfy withholding obligations, 29,050 shares were automatically sold: 9,869 shares on 2026-03-02 at a weighted average price of $11.66 ($115,052) and 19,181 shares on 2026-03-03 at a weighted average price of $11.76 ($225,500). Total proceeds ≈ $340,552. These sales were mandatory sell-to-cover transactions (not discretionary trades).

Key Details

  • Transaction dates and prices:
    • RSU grants: 2026-03-01 — 139,400 RSUs and 208,000 RSUs (both reported at $0.00).
    • Shares sold (tax withholding): 2026-03-02 — 9,869 shares @ weighted avg $11.66 (range $11.17–$11.91); 2026-03-03 — 19,181 shares @ weighted avg $11.76 (range $11.22–$12.095).
  • Shares sold to cover taxes totaled 29,050 shares for ≈ $340,552.
  • Shares owned after the transactions: Not specified in the filing.
  • Relevant footnotes:
    • F1: These RSUs represent the contingent right to receive one share per RSU; vesting: 25% on March 1 of 2027–2030, subject to continued service.
    • F2: The share sales were automatic sell-to-cover required to meet minimum statutory tax withholding — not discretionary sales by the reporting person.
    • F3/F4: Weighted-average price disclosures; specific per-share price breakdowns available on request.
    • F5: (Related vesting schedule language for option grants noted in filing.)
  • Filing timeliness: The Form 4 was filed 2026-03-03 for transactions beginning 2026-03-01; the filing does not indicate a late filing.

Context

  • These were RSU awards (contingent rights to future shares) rather than open-market purchases — awarding RSUs is a compensation event, not a buy signal. The subsequent sales were routine sell-to-cover transactions to satisfy tax withholding obligations and should not be read as discretionary insider selling.
  • For retail investors: awards increase potential future insider ownership if RSUs vest; automatic sell-to-cover reduces immediate share count but is common after equity awards and does not necessarily indicate management sentiment about the stock.

Insider Transaction Report

Form 4
Period: 2026-03-01
Entrada Therapeutics, Inc.TRDA
Doshi Dipal
DirectorCEO
Transactions
  • Award

    Common Stock

    [F1]
    2026-03-01+139,400→ 555,064 total
  • Tax Payment

    Common Stock

    [F2][F3]
    2026-03-02$11.66/sh−9,869$115,052→ 545,195 total
  • Tax Payment

    Common Stock

    [F2][F4]
    2026-03-03$11.76/sh−19,181$225,500→ 526,014 total
  • Award

    Stock Option (Right to Buy)

    [F5]
    2026-03-01+208,000→ 208,000 total
    Exercise: $11.93Exp: 2036-03-01→ Common Stock (208,000 underlying)
Footnotes (5)
  • [F1]Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
  • [F2]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.
Signature
/s/ Jared Cohen, as Attorney-in-Fact|2026-03-03

Documents

1 file
  • 4
    wk-form4_1772580082.xmlPrimary

    FORM 4